Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1023P is a processed pseudogene, meaning it is a nonfunctional copy of the U6 small nuclear RNA gene that has been integrated into the genome through retrotransposition, often mediated by LINE-1 elements[2][5]. Functional U6 snRNA is essential for the splicing of pre-mRNA and forms part of the catalytic center of the spliceosome, but pseudogene derivatives like RNU6-1023P do not produce a functional RNA and are considered molecular fossils. Such pseudogenes may serve as markers of retrotransposition activity in evolutionary or genome studies, but they have no active biological, molecular, or therapeutic role[2][3]. Key distinctions: - Functional U6 snRNA is vital for mRNA splicing, but pseudogenes like RNU6-1023P do not participate in this process[1][3]. - RNU6-1023P is one of many U6 snRNA-derived pseudogenes prevalent in the human and other mammalian genomes, generated via retrotransposition events and not retained for molecular function[2][5]. - This entry is based on genomic classification rather than pharmacological, biological, or therapeutic relevance. Summary: RNU6-1023P represents a genomic processed pseudogene, not a working receptor, enzyme, or therapeutic target. All entries relating to drugs, mechanism of action, disease roles, and biomarkers should be considered null, as the pseudogene does not participate in molecular or cellular activity relevant to therapeutics[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1023, pseudogene (RNU6-1023P).